---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Explore-CKD"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Explore-CKD. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Study outcomes, and 3 further headings. 68 evidence topics quoted from 10 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence/explore-ckd"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Explore-CKD

<a id="heading-3.1.5"></a>

## 3.1.5 Explore-CKD

<a id="heading-3.1.5.1"></a>

### 3.1.5.1 Objective

<a id="topic-3.1.5.1-1"></a>

#### Purpose stated in the ClinicalTrials.gov record

> “This is a randomized, double-blind (DB), placebo controlled, crossover study with a two-period, two-sequence (2x2) design evaluating the efficacy and safety of 25 mg QD lorundrostat (an aldosterone synthase inhibitor [ASI]) in addition to a SGLT2i for the treatment of hypertension in subjects with CKD and albuminuria while receiving stable treatment with an Angiotensin-converting enzyme inhibitor (ACEi) or an Angiotensin receptor blocker (ARB).”
> “A Randomized, Crossover, Double Blind, Placebo Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors, in Adults With Hypertension and Chronic Kidney Disease With Albuminuria”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.1-2"></a>

#### Aim stated in the published report

> “The trial’s aim was to evaluate the efficacy and safety of lorundrostat added to an SGLT2i in participants with uncontrolled hypertension, CKD, and persistent albuminuria despite receiving stable treatment with an ACEi or ARB.”
> “Building on this evidence, the present trial was designed to evaluate the efficacy and safety of lorundrostat in participants with uncontrolled hypertension and CKD.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.1-3"></a>

#### Purpose stated by the sponsor

> “The Explore-CKD trial was designed to provide data that augments the antihypertensive profile of lorundrostat by evaluating the efficacy and safety of lorundrostat in subjects with compromised renal function.”

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.5.2"></a>

### 3.1.5.2 Location and Study Date

<a id="topic-3.1.5.2-1"></a>

#### Study dates and status in the ClinicalTrials.gov record

> “Study Start (Actual)”
> “2023-12-14”
> “Primary Completion (Actual)”
> “2025-02-27”
> “Study Completion (Actual)”
> “2025-04-23”
> “Results First Posted”
> “2026-06-03”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.2-2"></a>

#### Registered locations

> “This study has 44 locations”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.2-3"></a>

#### Sites and enrollment period in the published report

> “Explore-CKD (ClinicalTrials.gov identifier NCT06150924) was a phase 2, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-sequence crossover trial conducted at 42 sites in the United States.”
> “Between December 14, 2023, and April 23, 2025, a total of 378 participants underwent screening, of whom 85 entered the run-in period and 59 were randomized 1:1 to the 2 treatment sequences”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.2-4"></a>

#### Sites stated by the sponsor

> “Explore-CKD randomized 59 participants at 42 sites in the United States.”

Source: [Mineralys Therapeutics press release, Explore-CKD publication (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/124/mineralys-therapeutics-announces-publication-of-phase-2)

<a id="topic-3.1.5.2-5"></a>

#### Other study identifiers

> “MLS-101-206”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="heading-3.1.5.3"></a>

### 3.1.5.3 Study Design

<a id="topic-3.1.5.3-1"></a>

#### Two-period, two-sequence crossover design

> “Explore-CKD (ClinicalTrials.gov identifier NCT06150924) was a phase 2, multicenter, randomized, double-blind, placebo-controlled, 2-period, 2-sequence crossover trial conducted at 42 sites in the United States.”
> “After a screening period of up to 2 weeks, eligible participants entered a 2-week run-in period where SGLT2i-naive participants began trial-provided dapagliflozin 10 mg once daily (Figure 1).”
> “Participants with SBP ≥135–180 mm Hg at the end of run-in period were eligible to be randomized 1:1 to lorundrostat 25 mg once daily–placebo arm or placebo–lorundrostat 25 mg once daily arm in 4-week treatment sequences, with a 4-week washout in between the treatment sequences.”
> “After randomization, clinical visits were conducted at weeks 2, 4, 8, 10, and 12 (the last visit of the treatment period) (Figure 1).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.3-2"></a>

#### Study periods in the ClinicalTrials.gov record

> “The study consists of up to a 2-week Screening period, a 2-week run-in period where subjects will either begin study provided dapagliflozin 10 mg or continue on their regularly prescribed SGLT2i, and two DB 4-week treatment periods separated by a 4-week washout period. Subjects will be randomized (1:1) to two treatment sequences: lorundrostat-placebo (LP) and placebo-lorundrostat (PL).”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.3-3"></a>

#### Design details in the ClinicalTrials.gov record

| Field | Quoted record |
| --- | --- |
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Crossover Assignment” |
| Phase | “Phase 2” |
| Enrollment (actual) | “60” |

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.3-4"></a>

#### Blood pressure measurement procedure

> “Unattended AOBP was assessed at each study visit.”
> “Each site was provided with an identical automated oscillometric blood pressure device (WatchBP Office AFIB, Microlife AG), training, and an instruction manual for collecting blood pressure measurements.”
> “After an initial 5-minute rest phase, 5 unattended seated measurements were performed with a 1-minute interval between each reading; the last 4 measures were used to calculate the average to reduce within-participant variance in measuring blood pressure.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.3-5"></a>

#### Oversight and sponsor role

> “The trial was designed by Mineralys Therapeutics, with contribution from external scientific advisers.”
> “The Explore-CKD trial was funded by Mineralys Therapeutics.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="heading-3.1.5.4"></a>

### 3.1.5.4 Eligibility Criteria

<a id="topic-3.1.5.4-1"></a>

#### Key inclusion and exclusion criteria in the published report

> “Eligible participants were ≥18 years of age with uncontrolled hypertension (seated automated office SBP [AOSBP] 135–180 mm Hg) and CKD stage 1–3b (eGFR ≥30 ml/min per 1.73 m2 based on creatinine estimation”
> “Participants were required to have received stable treatment with an ACEi or ARB for at least 4 weeks before screening.”
> “Key exclusion criteria were serum potassium >5.0 mmol/l, serum sodium <135 mmol/l, eGFR <30 ml/min per 1.73 m2, and uncontrolled diabetes (glycated hemoglobin >10%).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.4-2"></a>

#### Major inclusion criteria in the ClinicalTrials.gov record

> “At Screening, UACR of 200-5000 mg/g, inclusive, in first morning urine void”
> “At Screening, eGFRs of ≥30 mL/min/1.73 m2”
> “At Screening, AOBP SBP of 135-180 mmHg, inclusive”
> “On a stable treatment with an ACEi or ARB for at least 2 months prior to Screening”
> “At Screening, body mass index (BMI) of >18 kg/m2”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.4-3"></a>

#### Major exclusion criteria in the ClinicalTrials.gov record

> “At Screening, serum potassium >5.0 mmol/L”
> “History of clinically significant hyponatremia within 1 year prior to Screening”
> “Use of epithelial sodium channel (ENaC) inhibitors or Mineralocorticoid receptor antagonist (MRAs), including, but not limited to amiloride, triamterene, spironolactone, eplerenone, finerenone, from 4 weeks prior to the Screening Visit and during study participation. With the exception of MRAs in primary aldosteronism”
> “Medical history of kidney disease related to autoimmune diseases (lupus, anti-neutrophil cytoplasmic antibody [ANCA] vasculitis), multiple myeloma or other known paraproteins, infiltrative diseases of the kidney, obstructive nephropathy, cystic kidney diseases, and renal transplantation”
> “Medical history of advanced liver disease, including cirrhosis”
> “Diabetes mellitus with a glycosylated hemoglobin (HbA1c) >10% (>86 mmol/mol) at Screening”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.4-4"></a>

#### Ages eligible in the ClinicalTrials.gov record

> “18 Years and older”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.4-5"></a>

#### Chronic kidney disease stages described by the sponsor

> “Explore-CKD evaluated the safety and efficacy of 25 mg once daily (QD) lorundrostat in addition to a sodium-glucose cotransporter 2 (SGLT2) inhibitor for the treatment of hypertension in participants with Stage 2 to 3b CKD and albuminuria despite receiving stable treatment with an angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blocker (ARB).”

Source: [Mineralys Therapeutics Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1933414/000193341426000056/mlys-20251231.htm)

<a id="heading-3.1.5.5"></a>

### 3.1.5.5 Treatment

<a id="topic-3.1.5.5-1"></a>

#### Lorundrostat 25 mg or placebo once daily on background ACEi or ARB and SGLT2 inhibitor

> “Participants already receiving an SGLT2i could either switch to trial-provided dapagliflozin or continue with their prescribed SGLT2i.”
> “All participants were maintained on background therapy with an ACEi or ARB and an SGLT2i during the trial.”
> “Lorundrostat or matching placebo tablets were administered orally once daily at approximately the same time each morning.”
> “Participants were reminded about taking their trial medication using a smartphone application (AiCure).”
> “A dose modification to 12.5 mg was allowed for safety reasons on the basis of each participant’s safety data.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.5-2"></a>

#### Treatment sequences in the ClinicalTrials.gov record

> “Period 1 - Lorundrostat 25mg QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Placebo QD + SGLT2i QD 4 weeks”
> “Period 1 - Placebo QD + SGLT2i QD 4 weeks; Washout - Placebo QD + SGLT2i QD 4 weeks; Period 2 - Lorundrostat 25mg + SGLT2i QD 4 weeks”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="heading-3.1.5.6"></a>

### 3.1.5.6 Study Outcomes

<a id="heading-3.1.5.6.1"></a>

#### 3.1.5.6.1 Rationale for Using Change in Automated Office Systolic Blood Pressure as the Primary Endpoint

<a id="topic-3.1.5.6.1-1"></a>

##### Primary endpoint

> “The primary efficacy end point was the placebo-adjusted change in AOSBP.”
> “Efficacy end points were assessed after completion of each 4-week randomized treatment period (Figure 1).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-2"></a>

##### Registered primary outcome measure

> “Placebo-adjusted Change From Baseline in Automated Office Blood Pressure (AOBP) Systolic Blood Pressure (SBP) at Week 4”
> “Baseline to Week 4”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.6.1-3"></a>

##### Blood pressure control in chronic kidney disease

> “Adequate blood pressure control in individuals with CKD has been demonstrated to not only slow progression of renal damage but also reduce the risk of cardiovascular disease.”
> “Approximately 76% of people with comorbid CKD and hypertension have uncontrolled blood pressure despite treatment with multiple antihypertensive medications.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-4"></a>

##### Clinical relevance of the systolic blood pressure reduction stated by the investigators

> “Blood pressure improvement of this magnitude is known to be clinically relevant in patients with CKD.”
> “A meta-analysis of 26 randomized clinical trials of antihypertensive therapy in participants with or without CKD demonstrated that each 5-mm Hg reduction in SBP reduced the risk of major cardiovascular events by approximately 18%, with similar results observed for different medication classes and in patients with different eGFR levels.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-5"></a>

##### Blood pressure reduction as the basis of cardiovascular benefit in FDA labeling guidance

> “The similar effects with multiple drug classes with disparate mechanisms of action indicate that it is the decrease in blood pressure, rather than any other property of the drugs, that is largely responsible for these benefits.”
> “Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.”

Source: [FDA guidance, hypertension labeling for cardiovascular outcome claims (2011)](https://www.fda.gov/media/134777/download)

<a id="topic-3.1.5.6.1-6"></a>

##### Systolic blood pressure reduction and major cardiovascular events in an individual participant data meta-analysis

> “a 5 mm Hg reduction of systolic blood pressure reduced the risk of major cardiovascular events by about 10%, irrespective of previous diagnoses of cardiovascular disease”

Source: [Blood Pressure Lowering Treatment Trialists' Collaboration (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8102467/)

<a id="topic-3.1.5.6.1-7"></a>

##### Automated office blood pressure measurement

> “AOBP can be performed with or without staff being present, which is referred to as attended and unattended AOBP, respectively.”
> “Several studies have reported that BP measured with AOBP versus the auscultatory method is closer to awake out-of-office BP levels measured with ambulatory BP monitoring (ABPM).”

Source: [Muntner et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11409525/)

<a id="topic-3.1.5.6.1-8"></a>

##### Unattended compared with attended automated office blood pressure

> “The unattended systolic BP and diastolic BP were −2.7 (−4.7 to −0.6) and −0.9 (−1.8 to −0.1) mm Hg lower than attended BPs.”

Source: [Deragon et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12826897/)

<a id="topic-3.1.5.6.1-9"></a>

##### Exploratory endpoints

> “Exploratory end points included the change in 24-hour urine albumin and protein, automated office diastolic blood pressure, UACR (both spot urine and 24-hour urine), and eGFR.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-10"></a>

##### Rationale for albuminuria as an exploratory endpoint

> “Albuminuria is an independent predictor of kidney damage, and changes in UACR have been proposed as a surrogate end point in trials of CKD progression and end-stage renal disease.”
> “A meta-analysis of clinical trials and observational studies in patients with early-stage kidney disease found that a 30% reduction in UACR sustained over 1–2 years was associated with an approximately 20% lower risk of end-stage renal disease.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-11"></a>

##### Rationale for cystatin C estimated glomerular filtration rate

> “eGFR was estimated using the 2012 cystatin C Chronic Kidney Disease Epidemiology Collaboration equation to assess falsely elevated creatinine levels due to competition between lorundrostat and creatinine for the multidrug and toxin extrusion protein 1 transporter.”
> “eGFR was additionally estimated using the 2021 serum creatinine Chronic Kidney Disease Epidemiology Collaboration equation.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.6.1-12"></a>

##### Safety endpoints and adverse events of special interest

> “Safety was assessed throughout the trial as the incidence and severity of adverse events (AEs).”
> “AEs of special interest included modification of study drug dose, including dose reduction, dose hold, or permanent dose discontinuation due to hyperkalemia, hyponatremia, reduction in kidney function, or hypercortisolism (defined as morning serum cortisol >35 μg/dl, confirmed by 24-hour urinary free cortisol).”
> “Other AEs of special interest included symptomatic hypotension, severely elevated blood pressure (AOSBP >180 mm Hg or automated office diastolic blood pressure >110 mm Hg), and discontinuation of the trial drug due to hypocortisolism confirmed by an adrenocorticotropic hormone stimulation test.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="heading-3.1.5.7"></a>

### 3.1.5.7 Statistical Analysis Description

<a id="heading-3.1.5.7.1"></a>

#### 3.1.5.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.5.7.1-1"></a>

##### Planned sample size and power

> “A sample size of 60 participants randomized in a 1:1 ratio to the 2 sequences (lorundrostat 25 mg once daily–placebo and placebo–lorundrostat 25 mg once daily) had 85% power to detect a placebo-adjusted reduction in AOSBP ≥5.5 mm Hg pooling both treatment periods in a joint longitudinal analysis, assuming 14 mm Hg as an SD of change on the basis of data from completed lorundrostat clinical trials.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.1-2"></a>

##### Participants screened and randomized in the published report

> “Between December 14, 2023, and April 23, 2025, a total of 378 participants underwent screening, of whom 85 entered the run-in period and 59 were randomized 1:1 to the 2 treatment sequences (lorundrostat 25 mg once daily–placebo, n = 30; placebo–lorundrostat 25 mg once daily, n = 29) (Figure 2).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.1-3"></a>

##### Enrollment in the ClinicalTrials.gov record

> “Enrollment (Actual)”
> “60”

Source: [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.7.1-4"></a>

##### Participants analyzed in the posted results

| Analysis | Placebo | Lorundrostat |
| --- | --- | --- |
| Primary outcome, overall number of participants analyzed | “58” | “58” |
| All-cause mortality, affected / at risk (%) | “0/57 (0.00%)” | “0/58 (0.00%)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.7.2"></a>

#### 3.1.5.7.2 Description of Analysis Sets

<a id="topic-3.1.5.7.2-1"></a>

##### Estimand and handling of missing data for the primary endpoint

> “All P values are provided as 2-sided with 95% confidence intervals.”
> “The primary end point followed the treatment policy approach by using all observed efficacy data regardless of possible treatment discontinuation.”
> “Data missing due to intercurrent events were considered not missing at random and were imputed by the jump to reference (placebo) approach. Other missing data were imputed as missing at random.”
> “The primary end point was analyzed on 1000 multiply imputed data sets.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.2-2"></a>

##### Crossover model, sensitivity analysis, and parallel-group analyses

> “The mixed model included 2 baselines (week 0 for treatment period 1 and week 8 for treatment period 2).”
> “A sensitivity analysis was performed using a mixed-effects model, including treatment, period, and sequence as fixed factors, participants as a random factor, and a baseline value (week 0 or week 8) as a covariate.”
> “The analysis of change in spot UACR was performed on log-transformed values using a single common baseline (treatment period 1 week 0) because no spot urine collection occurred at week 8.”
> “To further validate the results, we analyzed differences in AOSBP and 24-hour UACR changes between placebo- and lorundrostat-treated subjects during each treatment period as 2 stand-alone, parallel randomized controlled trials (Supplementary Table S1).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.2-3"></a>

##### Attribution of adverse events to treatment periods

> “AEs reported during the washout period or during the safety follow-up period were assigned to the treatment received in treatment period 1 or treatment period 2, respectively.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.7.2-4"></a>

##### Adverse event reporting in the posted results

> “Adverse events that occurred during the Washout Period were attributed to treatment administered during Treatment Period 1. Adverse events that occurred during the Safety Follow-up Period were considered TEAEs if they occurred within 14 days of the start of the Safety Follow-up Period and were attributed to administered during Treatment Period 2.”
> “Placebo, pooled across both randomization sequence cohorts”
> “Lorundrostat, pooled across both randomization sequence cohorts”

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.8"></a>

### 3.1.5.8 Results

<a id="heading-3.1.5.8.1"></a>

#### 3.1.5.8.1 Participant Disposition

<a id="topic-3.1.5.8.1-1"></a>

##### Screening, randomization, and open-label extension enrollment

> “Between December 14, 2023, and April 23, 2025, a total of 378 participants underwent screening, of whom 85 entered the run-in period and 59 were randomized 1:1 to the 2 treatment sequences (lorundrostat 25 mg once daily–placebo, n = 30; placebo–lorundrostat 25 mg once daily, n = 29) (Figure 2).”
> “A majority (54 of 59) of participants enrolled in an ongoing open-label extension (OLE) trial (ClinicalTrials.gov identifier NCT05968430).”
> “Three participants discontinued treatment because of AEs, 2 attributed to lorundrostat treatment (hyperkalemia/acute kidney injury and CKD worsening) and 1 to placebo treatment (retinal detachment).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.1-2"></a>

##### Participant flow in the posted results

| Milestone | Cohort 1 (lorundrostat, then placebo) | Cohort 2 (placebo, then lorundrostat) |
| --- | --- | --- |
| Started | “30” | “29” |
| Completed | “29” | “28” |
| Not completed | “1” | “1” |
| Reason not completed: physician decision | “1” | “1” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.8.2"></a>

#### 3.1.5.8.2 Baseline Characteristics

<a id="topic-3.1.5.8.2-1"></a>

##### Demographic and disease characteristics in the published report

> “Baseline demographic and disease characteristics were similar between the 2 randomized sequences and are listed in Table 1.”
> “Participants were 69.5% male and 66.1% white, with a mean age of 64.6 years and a mean body mass index of 33.1 kg/m2.”
> “At baseline, the mean AOSBP was 148.9 mm Hg, the automated office diastolic blood pressure was 82.0 mm Hg, the geometric mean spot UACR was 516.8 mg/g, and the mean eGFR (creatinine) was 54.6 ml/min per 1.73 m2.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.2-2"></a>

##### Baseline characteristics table (N = 59)

| Characteristic | Value |
| --- | --- |
| Age, years, mean ± SD | “64.6 ± 10.14” |
| Age 75 years or older, n (%) | “13 (22.0)” |
| Male, n (%) | “41 (69.5)” |
| Female, n (%) | “18 (30.5)” |
| White, n (%) | “39 (66.1)” |
| Black or African American, n (%) | “10 (16.9)” |
| Hispanic or Latino, n (%) | “25 (42.4)” |
| Body mass index, kg/m2, mean ± SD | “33.1 ± 7.10” |
| Seated automated office systolic blood pressure, mm Hg, mean ± SD | “148.9 ± 10.37” |
| Seated automated office diastolic blood pressure, mm Hg, mean ± SD | “82.0 ± 10.49” |
| eGFR (cystatin C), ml/min per 1.73 m2, mean ± SD | “43.0 ± 14.97” |
| eGFR (creatinine), ml/min per 1.73 m2, mean ± SD | “54.6 ± 21.08” |
| UACR (24 hr), mg/g, geometric mean ± SD | “559 ± 2.55” |
| Two or fewer antihypertensive medications, n (%) | “21 (35.6)” |
| Three or more antihypertensive medications, n (%) | “38 (64.4)” |
| β-Blockers, n (%) | “28 (47.5)” |
| Selective calcium-channel blockers with mainly vascular effects, n (%) | “30 (50.8)” |
| Type 2 diabetes mellitus, n (%) | “45 (76.3)” |
| SGLT2i-naive at screening, n (%) | “26 (44.1)” |

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.2-3"></a>

##### Baseline systolic blood pressure by sequence in the posted results

| Group | Seated automated office systolic blood pressure, mmHg, mean (SD) |
| --- | --- |
| Cohort 1 (lorundrostat, then placebo) | “147.008(9.8704)” |
| Cohort 2 (placebo, then lorundrostat) | “150.802(10.6962)” |
| Total | “148.873(10.3731)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="heading-3.1.5.8.3"></a>

#### 3.1.5.8.3 Efficacy Results

<a id="topic-3.1.5.8.3-1"></a>

##### Primary endpoint: change in automated office systolic blood pressure at week 4

> “Four weeks of lorundrostat treatment resulted in a statistically significant reduction in AOSBP compared with placebo.”
> “The least squares (LS) mean change from baseline AOSBP was −9.3 mm Hg for lorundrostat and −1.8 mm Hg for placebo (placebo-adjusted change −7.5 mm Hg; 95% confidence interval −12.3 to −2.7 mm Hg; P = 0.0024) (Figure 3a).”
> “The mean baseline AOSBP was reduced from 143.3 ± 12.90 to 134.6 ± 13.99 mm Hg with lorundrostat treatment and from 144.6 ± 14.41 to 142.4 ± 15.5 mm Hg with placebo (Figure 3b).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-2"></a>

##### Period and carryover effects

> “There was no evidence of a period (P = 0.6821) or carryover (P = 0.7384) effect for SBP evaluated using the model described in Lim and In.”
> “The absence of a carryover effect (P = 0.7234) was reconfirmed using a model described in Shen and Luz.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-3"></a>

##### Primary outcome in the posted results

| Measure | Placebo | Lorundrostat |
| --- | --- | --- |
| Least squares mean change from baseline, mmHg | “-1.755” | “-9.253” |
| 90% confidence interval | “(-4.966 to 1.455)” | “(-12.453 to -6.053)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.8.3-4"></a>

##### Automated office diastolic blood pressure

> “Automated office diastolic blood pressure was reduced by 3.9 mm Hg with lorundrostat and 1.4 mm Hg with placebo (LS mean difference −2.6 mm Hg) (Supplementary Figure S2).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-5"></a>

##### Albuminuria and proteinuria

> “All proteinuria indices decreased from baseline by 20.9%–30.5% with lorundrostat treatment.”
> “The placebo-adjusted LS mean percent change in proteinuria for lorundrostat versus placebo was significant for all 3 indices: −25.6% (P = 0.0015) for spot UACR, −26.1% (P < 0.0001) for 24-hour UACR, and −22.1% (P = 0.0002) for 24-hour urine protein-to-creatinine ratio (Figure 4).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-6"></a>

##### Estimated glomerular filtration rate

> “The LS mean decrease in cystatin C–estimated eGFR was 2.74 ml/min per 1.73 m2 with lorundrostat and 0.77 ml/min per 1.73 m2 with placebo, corresponding to a placebo-adjusted decrease of 1.97 ml/min per 1.73 m2 (95% confidence interval −3.83 to −0.11 ml/min per 1.73 m2; P = 0.0380) and a placebo-adjusted percent change of −4.58% (P = 0.0362).”
> “The LS mean decrease in creatinine-estimated eGFR was 8.42 ml/min per 1.73 m2 with lorundrostat and 2.34 ml/min per 1.73 m2 with placebo, corresponding to a placebo-adjusted decrease of 6.09 ml/min per 1.73 m2 (95% confidence interval −8.12 to −4.05 ml/min per 1.73 m2; P < 0.0001) and a placebo-adjusted percent change in creatinine-estimated eGFR of −11.39% (P < 0.0001).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-7"></a>

##### Aldosterone and renin

> “The geometric mean serum aldosterone level decreased by 41.5% during treatment with lorundrostat and increased by 1.8% during placebo treatment. The geometric mean plasma renin activity increased by 75.2% with lorundrostat and 4.2% with placebo. The geometric mean aldosterone-to-renin ratio decreased by 67.2% during treatment with lorundrostat and by 5.8% with placebo.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.3-8"></a>

##### Topline results table in the sponsor release

| Measure | Placebo | Lorundrostat 25 mg | Placebo-adjusted |
| --- | --- | --- | --- |
| Change in systolic BP (mmHg), primary endpoint | “-1.76” | “-9.25” | “-7.5 (p=0.0024)” |
| Change in spot UACR (mg/g) | “-6.60%” | “-30.51%” | “-25.60% (p=0.0015)” |
| Change in eGFR, cystatin C (mL/min/1.73m2) | “-2.20%” | “-6.78%” | “-4.58% (p=0.0362)” |

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="topic-3.1.5.8.3-9"></a>

##### Analysis basis of the topline estimates

> “Per protocol Systolic BP, UACR, and eGFR estimates and p values from Mixed Effects Model for a crossover trial with multiple baselines.”

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.5.8.4"></a>

#### 3.1.5.8.4 Health-related Quality of Life and Patient-reported Outcomes

No evidence found.

<a id="heading-3.1.5.8.5"></a>

#### 3.1.5.8.5 Safety Results

<a id="topic-3.1.5.8.5-1"></a>

##### Treatment-emergent adverse events

> “Ninety treatment-emergent AEs (TEAEs) were reported by 48 participants (Table 2).”
> “At least 1 TEAE was reported by 29 of 58 participants on lorundrostat (50%) and by 19 of 57 participants during placebo treatment (33%).”
> “TEAEs considered related to treatment occurred in 16 participants while receiving lorundrostat (27.6%) and 8 participants while receiving placebo (14.0%).”
> “Most treatment-related TEAEs were considered mild to moderate in severity, with 2 severe events occurring in 1 participant in the lorundrostat group (1.7%). There were no severe TEAEs with placebo treatment.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-2"></a>

##### Overview of treatment-emergent adverse events, n (%) and number of events

| Event | Placebo (n = 57) | Lorundrostat (n = 58) |
| --- | --- | --- |
| TEAEs | “19 (33.3) [36]” | “29 (50.0) [54]” |
| Treatment-related TEAEs | “8 (14.0) [9]” | “16 (27.6) [24]” |
| Serious adverse events | “0 (0.0) [0]” | “2 (3.4) [4]” |
| Adverse events of special interest | “1 (1.8) [1]” | “10 (17.2) [13]” |
| TEAEs leading to discontinuation of the trial drug | “1 (1.8) [1]” | “2 (3.4) [3]” |
| TEAEs leading to dose modification of the trial drug | “4 (7.0) [4]” | “12 (20.7) [15]” |
| Death | “0 (0.0) [0]” | “0 (0.0) [0]” |

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-3"></a>

##### Most common adverse events

> “The most commonly reported TEAEs during placebo or lorundrostat treatment were hyperkalemia (lorundrostat, n = 9 [15.5%]; placebo, n = 2 [3.5%]), GFR decrease (lorundrostat, n = 6 [10.3%]; placebo, n = 2 [3.5%]), hyponatremia (lorundrostat, n = 3 [5.2%]; placebo, n = 3 [5.3%]), and hypotension (lorundrostat, n = 3 [5.2%]; placebo, n = 2 [3.5%])”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-4"></a>

##### Adverse events of special interest and discontinuations

> “AEs of special interest were experienced by 10 participants with lorundrostat treatment (17.2%) and 1 participant with placebo (1.8%).”
> “Per protocol modification of the study drug dose due to hyperkalemia and reduction in kidney function were the most common AEs of special interest, occurring in 8.6% (n = 5) and 10.3% (n = 6) of participants during lorundrostat treatment, respectively, versus none with placebo.”
> “Three participants discontinued treatment because of AEs, 2 attributed to lorundrostat treatment (hyperkalemia/acute kidney injury and CKD worsening) and 1 to placebo treatment (retinal detachment). There were no deaths reported during the trial (Table 2).”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-5"></a>

##### Hyperkalemia

> “Three participants (5.2%) had confirmed serum potassium of >6.0 mmol/l while under lorundrostat treatment (Table 3).”
> “Hyperkalemic events occurred in participants receiving background ACEi/ARB and SGLT2i therapy.”
> “In this trial, increases in serum potassium were managed with lorundrostat dose reduction, temporary dose interruption, and/or standard medical management, including potassium binders.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-6"></a>

##### Participants with at least 1 confirmed elevated potassium value, n (%)

| Prespecified level | Placebo (n = 57) | Lorundrostat (n = 58) |
| --- | --- | --- |
| Level 1: >5.5–6.0 mmol/l | “1 (1.8)” | “4 (6.9)” |
| Level 2: >6.0–6.5 mmol/l | “0 (0.0)” | “2 (3.4)” |
| Level 3: >6.5 mmol/l | “0 (0.0)” | “1 (1.7)” |

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-7"></a>

##### Sodium, kidney function, and cortisol

> “No serum sodium values <125 mmol/l occurred (Supplementary Table S6). Nine participants experienced an eGFR (cystatin C) decrease ≥25%.”
> “There were no eGFR decreases ≥50% (Supplementary Table S7), and no participants had a ≥2-fold elevation in serum creatinine. No clinically meaningful changes in serum cortisol were observed in either treatment sequence.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.8.5-8"></a>

##### Serious adverse events in the posted results

| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
| --- | --- | --- |
| Total | “0/57 (0.00%)” | “2/58 (3.45%)” |
| Influenza | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Hyperkalaemia | “0/57 (0.00%)” | “1/58 (1.72%)” |
| Acute kidney injury | “0/57 (0.00%)” | “1/58 (1.72%)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.8.5-9"></a>

##### Other adverse events in the posted results (frequency threshold 2%)

| Event | Placebo, affected / at risk (%) | Lorundrostat, affected / at risk (%) |
| --- | --- | --- |
| Total | “18/57 (31.58%)” | “29/58 (50.00%)” |
| Glomerular filtration rate decreased | “2/57 (3.51%)” | “6/58 (10.34%)” |
| Hyperkalaemia | “2/57 (3.51%)” | “9/58 (15.52%)” |
| Hyponatraemia | “3/57 (5.26%)” | “3/58 (5.17%)” |
| Hypotension | “2/57 (3.51%)” | “3/58 (5.17%)” |
| Orthostatic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |
| Diastolic hypotension | “1/57 (1.75%)” | “2/58 (3.45%)” |

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.8.5-10"></a>

##### Discontinuations reported in the topline release

> “During lorundrostat treatment, one subject discontinued treatment due to elevation of potassium associated with reduced eGFR and one subject discontinued treatment due to reduction in eGFR alone.”

Source: [Mineralys Therapeutics press release, Explore-CKD topline results (2025)](https://ir.mineralystx.com/news-events/press-releases/detail/73/mineralys-therapeutics-announces-positive-topline-results)

<a id="heading-3.1.5.9"></a>

### 3.1.5.9 Study Limitations

<a id="topic-3.1.5.9-1"></a>

#### Summary

Explore-CKD was a phase 2, two-period, two-sequence crossover trial with 4-week treatment periods separated by a 4-week washout. The publication reports 59 randomized participants at 42 sites in the United States; the registry lists an enrollment of 60 and 44 locations. One dose, lorundrostat 25 mg once daily, was studied. The primary endpoint was the placebo-adjusted change in automated office systolic blood pressure; albuminuria, proteinuria, and eGFR were exploratory endpoints, and no kidney or cardiovascular outcome was assessed. The investigators state that the 4-week treatment period “does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes” and that the findings “will require confirmation in a larger, longer-duration, parallel-arm trial”. Participants with serum potassium above 5.0 mmol/L at screening were excluded, which, with the short treatment duration, the investigators state “could underestimate hyperkalemia risk in routine clinical practice”; hyperkalemia was reported in 9 of 58 participants (15.5%) during lorundrostat treatment and 2 of 57 (3.5%) during placebo. The registry requires stable ACEi or ARB treatment for at least 2 months before screening, and the publication states at least 4 weeks. The trial was designed and funded by Mineralys Therapeutics, three authors are company employees, and no health-related quality of life or patient-reported outcome was reported.

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021); [ClinicalTrials.gov NCT06150924](https://clinicaltrials.gov/study/NCT06150924)

<a id="topic-3.1.5.9-2"></a>

#### Limitations stated by the investigators

> “This trial has certain limitations. The 4-week treatment period captures short-term effects but does not assess the durability of blood pressure lowering or longer-term safety and clinical outcomes, including hyperkalemia and renal and cardiovascular events. As an exploratory study, these findings will require confirmation in a larger, longer-duration, parallel-arm trial.”
> “Importantly, the short 4-week treatment duration and the exclusion of participants with baseline serum potassium >5.0 mmol/l should be considered when interpreting these data, as both may limit generalizability and could underestimate hyperkalemia risk in routine clinical practice.”
> “The results of the second treatment period can be influenced by carryover from the first treatment period; to address this, we used a 4-week washout period between the treatments.”
> “In longer-term studies of RAAS inhibition, similar hemodynamic effects have been associated with renal protection; however, the present study was not designed to assess long-term renoprotective outcomes.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-3.1.5.9-3"></a>

#### Limitations and caveats in the posted results

> “Limitations of this study include the small sample size and short treatment duration. The 4-week primary endpoint captures short-term pharmacodynamic effects but not the durability of long-term BP lowering or renal outcomes. Second, while urinary protein reduction is a validated surrogate marker for renal risk, confirmation with eGFR slope over longer time periods will be essential.”

Source: [ClinicalTrials.gov NCT06150924 results](https://clinicaltrials.gov/study/NCT06150924?tab=results)

<a id="topic-3.1.5.9-4"></a>

#### Sponsor role and author disclosures

> “SB, MN, and DR are employees of Mineralys Therapeutics.”
> “The trial was designed by Mineralys Therapeutics, with contribution from external scientific advisers.”
> “Medical writing and editorial support was provided by John Watson, PhD, Jonathan Mitchell, PharmD, and Courtney Breuel, ELS, of the Sensified division of Woven Health Collective, LLC (New York, NY), and was funded by Mineralys Therapeutics.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
